0001841401-22-000004.txt : 20221201 0001841401-22-000004.hdr.sgml : 20221201 20221201195851 ACCESSION NUMBER: 0001841401-22-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221129 FILED AS OF DATE: 20221201 DATE AS OF CHANGE: 20221201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wahl Bryan CENTRAL INDEX KEY: 0001841401 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 221440019 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wf-form4_166994271203193.xml FORM 4 X0306 4 2022-11-29 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001841401 Wahl Bryan C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 0 1 0 0 General Counsel Common Stock 2022-11-29 4 M 0 10251 0 A 17224 D Common Stock 2022-11-30 4 S 0 1183 16.50 D 16041 D Common Stock 2022-12-01 4 S 0 1164 16.75 D 14877 D Restricted Stock Units 2022-11-29 4 M 0 10251 0 D Common Stock 10251.0 23920 D The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022. Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. /s/ Leonard M. Greenstein, Attorney-in-Fact 2022-12-01